Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with huntington disease

Clinical Neuropharmacology

Volumn 34, Issue 3, 2011, Pages 95-100

  Esmaeilzadeh, Mouna ^a   Kullingsjö, Johan ^b   Ullman, Henrik ^b   Varrone, Andrea ^a   Tedroff, Joakim ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NeuroSearch Sweden AB   (Sweden)

Author keywords

ACR16; brain metabolism; FDG PET imaging; Huntington disease; pridopidine

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; PRIDOPIDINE;

ADULT; AGED; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; HUNTINGTON CHOREA; MALE; METABOLIC RATE; OPEN STUDY; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; RATING SCALE; THALAMUS DORSOMEDIAL NUCLEUS;

ADULT; AGED; BRAIN; ENERGY METABOLISM; FEMALE; GLUCOSE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 79959200768     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31821c31d8     Document Type: Article

References (31)

1. Walker FO. Huntington's disease. Lancet 2007;369:218-228. (Pubitemid 46107685)
2. Folstein S. Huntington's Disease: A Disorder of Families. Baltimore, MD: Johns Hopkins University Press; 1989.
3. Albin R, Young A, Penney J, et al. Selective neurodegeneration in Huntington's disease. Ann Neurol 1995;38:835-836. (Pubitemid 26004064)
4. Gutekunst C, Norflus F, Hersch S. The neuropathology of Huntington's disease. In: Bates G, Harper P, Jones L, eds. Huntington's Disease. New York, NY: Oxford University Press; 2002:251-275.
5. Rosas HD, Hevelone ND, Zaleta AK, et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005;65:745-747. (Pubitemid 41285856)
6. Jueptner M, Weiller C. Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Neuroimage 1995;2:148-156.
7. Eidelberg D, Moeller J, Kazumata K, et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 1997;120:1315-1324. (Pubitemid 27344702)
8. Huang C, Mattis P, Tang C, et al. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007;34:714-723. (Pubitemid 44827754)
9. Feigin A, Leenders KL, Moeller JR, et al. Metabolic network abnormalities in early Huntington's disease: an [18F]FDG PET study. J Nucl Med 2001;42:1591-1595. (Pubitemid 33131316)
10. Feigin A, Tang C, Ma Y, et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007;130:2858-2867. (Pubitemid 350033965)
11. Dyhring T, Nielsen Eÿ, Sonesson C, et al. The dopaminergic stabilizers pridopidine (ACR16) and (j)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 2010;628:19-26.
12. Ponten H, Kullingsjö J, Lagerkvist S, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol 2010;644:88-95.
13. Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol 2010;33:260-264.
14. de Yebenes J, Landwehrmeyer B, Reilmann R, et al. Pridopidine improves motor function in patients with Huntington's disease-results from the phase 3 multinational European multicenter ACR16 study in Huntington's disease (MermaiHD). In: 14th International Congress of Parkinson's Disease and Movement Disorders. Buenos Aires: 2010.
15. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136.
16. Wienhard K, Dahlbom M, Eriksson L, et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994;18:110-118. (Pubitemid 24033867)
17. Roland P, Zilles K. Brain atlases-a new research tool. Trends Neurosci 1994;17:458-467. (Pubitemid 24321944)
18. Esmaeilzadeh M, Farde L, Karlsson P, et al. Extrastriatal dopamine D2 receptor binding in Huntington's disease. Hum Brain Mapp (in press).
19. Rhodes CG, Wise RJS, Gibbs JM, et al. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. An Neurol 1983;14:614-626. (Pubitemid 14211607)
20. Takikawa S, Dhawan V, Spetsieris P, et al. Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. Radiology 1993;188:131-136. (Pubitemid 23183112)
21. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. New York, NY: Thieme Medical; 1988.
22. Lancaster JL, Tordesillas-Gutièrrez D, Martinez M, et al. Bias between MNI and Talairach coordinates analyzed using the ICBM-152 brain template. Hum Brain Mapp 2007;28:1194-1205. (Pubitemid 350077483)
23. Pearson K. On lines and planes of closest fit to systems of points in space. Philosophical Magazine 1901;2:559-572.
24. Eriksson L, Johansson E, Kettaneh-Wold N, et al. Multi-and megavariate data analysis. PCA. Basic Principles and Applications. Umeå, Sweden: Umetrics AB; 2006.
25. Wold S. Cross-validatory estimation of the number of components in factor and principal component models. Technometrics 1978;20:397-405.
26. Jackson JE. A User's Guide to Principle Components. New York, NY: John Wiley and Sons; 1991.
27. Hotelling H. The generalization of Student's ratio. Ann Math Stat 1931;2:360-378.
28. 2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119:2085-2095. (Pubitemid 27032638)
29. Georgiou-Karistianis N, Sritharan A, Farrow M, et al. Increased cortical recruitment in Huntington's disease using a Simon task. Neuropsychologia 2007;45:1791-1800. (Pubitemid 46386115)
30. Kim J-S, Reading SAJ, Brashers-Krug T, et al. Functional MRI study of a serial reaction time task in Huntington's disease. Psychiatry Res 2004;131:23-30. (Pubitemid 38891791)
31. Feigin A, Ghilardi M-F, Huang C, et al. Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol 2006;59:53-59. (Pubitemid 43042871)